<PAGE> 1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
- --------------------------------------------------------------------------------
FORM 8-K/A
(Amendment No. 1)
- --------------------------------------------------------------------------------
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report: August 14, 1997
(Date of earliest event reported)
CONTOUR MEDICAL, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-26288 77-0163521
(State or other jurisdiction of (Commission file number) (I.R.S. Employer
incorporation or organization) Identification No.)
6025 SHILOH ROAD, SUITE A
ALPHARETTA, GEORGIA 30005
(Address of principal executive offices)
(770) 888-8528
(Registrant's telephone number, including area code)
<PAGE> 2
Item 4. Changes in the Registrant's Certifying Accountant.
On August 21, 1997, the Company filed a Current Report on Form 8-K reporting
the resignation of Coopers & Lybrand L.L.P. ("C&L") by letter dated August 14,
1997. The Company furnished a copy of the Form 8-K to C&L on the day it was
filed with the Securities and Exchange Commission (the "Commission") and
requested C&L furnish the Company with a letter addressed to the Commission, as
required by Item 304(a)(3) of Regulation S-K. On September 5, 1997, C&L
provided the Company with its response to the Company's Form 8-K, wherein it
agrees with the statements made by the Company therein.
The Company has engaged the accounting firm of Cherry, Beckaert & Holland,
L.L.P. to reaudit the Company's financial statements for the fiscal year ended
June 30, 1996 and to audit the Company's financial statements for the fiscal
year ended June 30, 1997.
A copy of C&L's response under Item 304 of Regulation S-K is attached hereto
as Exhibit 16.1.
Item 7. Financial Statements and Exhibits.
(a) Financial Statements: None.
(b) Pro Forma Financial Information: None
(c) Exhibits:
16.1 Letter of Coopers & Lybrand L.L.P. required by
Item 304(a)(3) of Regulation S-K.
2
<PAGE> 3
SIGNATURE
Pursuant to the requirements of Section 13 or 15(d) of the Securities
Exchange Act of 1934, the Company has duly caused this Report to be signed on
its behalf by the undersigned, thereunto duly authorized.
CONTOUR MEDICAL, INC.
By: /s/ Donald F. Fox
-----------------------------------
Donald F. Fox
Its President
Dated as of September 5, 1997.
3
<PAGE> 4
EXHIBIT INDEX
EXHIBIT NO. DESCRIPTION
16.1 Letter of Coopers & Lybrand L.L.P.
required by Item 304(a)(3) of
Regulation S-K.
<PAGE> 1
EXHIBIT 16.1
[COOPERS & LYBRAND LETTERHEAD]
September 5, 1997
Securities and Exchange Commission
450 5th Street, N.W.
Washington, D.C. 20549
Gentlemen:
We have read the statements made by Contour Medical, Inc. in Item 4 of its
Form 8-K, filed on August 21, 1997. We agree with the statements concerning
our Firm in such Form 8-K.
Very truly yours,
/s/ Coopers & Lybrand L.L.P.
Coopers & Lybrand L.L.P.
